Lipocine to Present at the 27th Annual ROTH Conference

SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- <u>Lipocine Inc.</u> (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Lipocine website, <u>www.lipocine.com</u>. Please log on through Lipocine's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on Lipocine's website for 90 days following the presentation.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's lead product candidate, LPCN 1021, demonstrated positive top-line efficacy results in Phase 3 testing and is targeted for testosterone replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth, and is currently in Phase 1 testing.

Forward-Looking Statements

This release contains "forward looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts relating to expectations regarding clinical trials, the potential uses and benefits of Lipocine's product candidates, and product development and commercialization efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to our products, expected product benefits, clinical and regulatory expectations and plans, regulatory developments and requirements, the receipt of regulatory approvals, the results of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine'sfilings with the U.S. Securities and Exchange Commission (the "SEC"), including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the Company's website at <u>www.lipocine.com</u> or on the SEC website at <u>www.sec.gov</u>. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

https://ir.lipocine.com/Lipocine-to-Present-at-the-27th-Annual-ROTH-Conference